C ommon diseases such as cardiovascular disease, cancer, obesity, diabetes, psychiatric illnesses and inflammatory diseases are caused by combinations of multiple genetic and environmental factors 1 . Discovering these genetic factors will provide fundamental new insights into the pathogenesis, diagnosis and treatment of human disease. Searches for causative variants in chromosome regions identified by linkage analysis have been highly successful for many rare single-gene disorders. By contrast, linkage studies have been much less successful in locating genetic variants that affect common complex diseases, as each variant individually contributes only modestly to disease risk 2, 3 . A complementary approach to identifying these specific genetic risk factors is to search for an association between a specific variant and a disease, by comparing a group of affected individuals with a group of unaffected controls 4 . In the absence of strong natural selection, there is likely to be a broad spectrum of frequency of such variants, many of which are likely to be common in the population. A number of association studies, focused on candidate genes, regions of linkage to a disease or more large-scale surveys, have already led to the discovery of genetic risk factors for common diseases. Examples include type 1 diabetes (human leukocyte antigen (HLA 5 ), insulin 6 and CTLA4 (ref. 7)), Alzheimer's disease (APOE) 8 , deep vein thrombosis (factor V) 9 , inflammatory bowel disease (NOD2 (refs 10, 11) and also 5q31 (ref. 12)), hypertriglyceridaemia (APOAV) 13 , type 2 diabetes (PPARG) 14, 15 , schizophrenia (neuregulin 1) 16 , asthma (ADAM33) 17 , stroke (PDE4D) 18 and myocardial infarction (LTA) 19 . One approach to doing association studies involves testing each putative causal variant for correlation with the disease (the 'direct' approach) 2 . To search the entire genome for disease associations would entail the substantial expense of whole-genome sequencing of numerous patient samples to identify the candidate variants 3 . At present, this approach is limited to sequencing the functional parts of candidate genes (selected on the basis of a previous functional or genetic hypothesis) for potential disease-associated candidate variants. An alternative approach (the 'indirect' approach) has been proposed 20 , whereby a set of sequence variants in the genome could serve as genetic markers to detect association between a particular genomic region and the disease, whether or not the markers themselves had functional effects. The search for the causative variants could then be limited to the regions showing association with the disease.
Two insights from human population genetics suggest that the indirect approach is able to capture most human sequence variation, with greater efficiency than the direct approach. First, ,90% of sequence variation among individuals is due to common variants 21 . Second, most of these originally arose from single historical mutation events, and are therefore associated with nearby variants that were present on the ancestral chromosome on which the mutation occurred. These associations make the indirect approach feasible to study variants in candidate genes, chromosome regions or across the whole genome. Prior knowledge of putative functional variants is not required. Instead, the approach uses information from a relatively small set of variants that capture most of the common patterns of variation in the genome, so that any region or gene can be tested for association with a particular disease, with a high likelihood that such an association will be detectable if it exists.
The aim of the International HapMap Project is to determine the common patterns of DNA sequence variation in the human genome, by characterizing sequence variants, their frequencies, and correlations between them, in DNA samples from populations with ancestry from parts of Africa, Asia and Europe. The project will thus provide tools that will allow the indirect association approach to be applied readily to any functional candidate gene in the genome, to any region suggested by family-based linkage analysis, or ultimately to the whole genome for scans for disease risk factors.
Common variants responsible for disease risk will be most readily approached by this strategy, but not all predisposing variants are common. However, it should be noted that even a relatively uncommon disease-associated variant can potentially be discovered using this approach. Reflecting its historical origins, the uncommon variant will be travelling on a chromosome that carries a characteristic pattern of nearby sequence variants. In a group of people affected by a disease, the rare variant will be enriched in frequency compared with its frequency in a group of unaffected controls. This observation, for example, was of considerable assistance in the identification of the genes responsible for cystic fibrosis 22 and diastrophic dysplasia 23 , after linkage had pointed to the general chromosomal region.
Below we provide a brief description of human sequence variation, and then describe the strategy and key components of the project. These include the choice of samples and populations for study, the process of community engagement or public consultation, selection of single-nucleotide polymorphisms (SNPs), genotyping, data release and analysis.
Human DNA sequence variation
Any two copies of the human genome differ from one another by approximately 0.1% of nucleotide sites (that is, one variant per 1,000 bases on average) [24] [25] [26] [27] . The most common type of variant, a SNP, is a difference between chromosomes in the base present at a particular site in the DNA sequence (Fig. 1a) . For example, some chromosomes in a population may have a C at that site (the 'C allele'), whereas others have a T (the 'Tallele'). It has been estimated that, in the world's human population, about 10 million sites (that is, one variant per 300 bases on average) vary such that both alleles are observed at a frequency of $1%, and that these 10 million common SNPs constitute 90% of the variation in the popu-lation 21, 28 . The remaining 10% is due to a vast array of variants that are each rare in the population. The presence of particular SNP alleles in an individual is determined by testing ('genotyping') a genomic DNA sample.
Nearly every variable site results from a single historical mutational event as the mutation rate is very low (of the order of 10 28 per site per generation) relative to the number of generations since the most recent common ancestor of any two humans (of the order of 10 4 generations). For this reason, each new allele is initially associated with the other alleles that happened to be present on the particular chromosomal background on which it arose. The specific set of alleles observed on a single chromosome, or part of a chromosome, is called a haplotype (Fig. 1b) . New haplotypes are formed by additional mutations, or by recombination when the maternal and paternal chromosomes exchange corresponding segments of DNA, resulting in a chromosome that is a mosaic of the two parental haplotypes 29 . The coinheritance of SNP alleles on these haplotypes leads to associations between these alleles in the population (known as linkage disequilibrium, LD). Because the likelihood of recombination between two SNPs increases with the distance between them, on average such associations between SNPs decline with distance. Many empirical studies have shown highly significant levels of LD, and often strong associations between nearby SNPs, in the human genome [30] [31] [32] [33] [34] . These strong associations mean that in many chromosome regions there are only a few haplotypes, and these account for most of the variation among people in those regions 31, 35, 36 . The strong associations between SNPs in a region have a practical value: genotyping only a few, carefully chosen SNPs in the region will provide enough information to predict much of the information about the remainder of the common SNPs in that region. As a result, only a few of these 'tag' SNPs are required to identify each of the common haplotypes in a region 35, [37] [38] [39] (Fig. 1c) . As the extent of association between nearby markers varies dramatically across the genome [30] [31] [32] 34, 35, 40 , it is not efficient to use SNPs selected at random or evenly spaced in the genome sequence. Instead, the patterns of association must be empirically determined for efficient selection of tag SNPs. On the basis of empirical studies, it has been estimated that most of the information about genetic variation represented by the 10 million common SNPs in the population could be provided by genotyping 200,000 to 1,000,000 tag SNPs across the genome 31, 36, 38, 39 . Thus, a substantial reduction in the amount of genotyping can be obtained with little loss of information, by using knowledge of the LD present in the genome.
For common SNPs, which tend to be older than rare SNPs, the patterns of LD largely reflect historical recombination and demographic events 41 . Some recombination events occur repeatedly at 'hotspots' 30, 42 . The result of these processes is that current chromosomes are mosaics of ancestral chromosome regions 29 . This explains the observations that haplotypes and patterns of LD are shared by apparently unrelated chromosomes within a population and generally among populations 43 . These observations are the conceptual and empirical foundation for developing a haplotype map of the human genome, the 'HapMap'. This map will describe the common patterns of variation, including associations between SNPs, and will include the tag SNPs selected to most efficiently and comprehensively capture this information.
The International HapMap Consortium
An initial meeting to discuss the scientific and ethical issues associated with developing a human haplotype map was held in Washington DC on 18-19 July 2001 (http://www.genome.gov/ 10001665). Groups were organized to consider the ethical issues, to develop the scientific plan and to choose the populations to include. The International HapMap Project (http://www.hapmap. org/) was then formally initiated with a meeting in Washington DC on 27-29 October 2002 (http://www.genome.gov/10005336). The participating groups and funding sources are listed in Table 1 .
DNA samples and populations
Human populations are the products of numerous social, historical and demographic processes. As a result, no populations are typical, special or sharply bounded 44, 45 . As most common patterns of variation can be found in any population 46 , no one population is essential for inclusion in the HapMap. Nonetheless, we decided to include several populations from different ancestral geographic locations to ensure that the HapMap would include most of the common variation and some of the less common variation in different populations, and to allow examination of various hypotheses about patterns of LD.
Studies of allele frequency distributions suggest that ancestral geography is a reasonable basis for sampling human populations 44, 47, 48 . Pilot studies using samples from the Yoruba, Japanese, Chinese and individuals with ancestry from Northern and Western Europe have shown substantial similarity in their haplotype patterns, although the frequencies of haplotypes often differ 31, 44 . Given these scientific findings, coupled with consideration of ethical, social and cultural issues, these populations were approached for inclusion in the HapMap through a process of community engagement or consultation (see Box 1) .
The HapMap developed with samples from these four large populations will include a substantial amount of the genetic variation found in all populations throughout the world. The goal of the HapMap is medical, and the common patterns of variation identified by the project will be useful to identify genes that contribute to disease and drug response in many other populations. Samples from several other populations are being collected for studies that will examine how similar their haplotype patterns are to those in the HapMap. If the patterns found are very different, samples from some of these populations may be genotyped on a large scale to make the HapMap more applicable to them. Further follow-up studies in other populations, small and large, are likely to be undertaken by scientists in many nations for common disease gene discovery. The project will study a total of 270 DNA samples: 90 samples (see Supplementary Information, part 1) 
.umdnj.edu/nigms/); cell lines and DNA from the new samples will be available from Coriell in early 2004 for future studies with research protocols approved by appropriate ethics committees. It is anticipated that other researchers will genotype additional SNPs in these samples in the future, and that these data will continuously improve the HapMap.
These samples will have population and sex identifiers without information that could link them to individual donors. As the goal of the project is solely to identify patterns of genetic variation, no medical or other phenotypic information will be included. About 50% more samples were collected than will be used, so that inclusion of a sample from any particular donor cannot be known.
Samples of 45 unrelated individuals should be sufficient to find 99% of haplotypes with a frequency of 5% or greater in a population. Studies of LD can use random individual samples, trios or larger pedigrees; each design has advantages (ease of sampling) and disadvantages (decreasing efficiency with increasing numbers of related individuals). Analysis of existing data and computer simulations suggested that unrelated individuals and trios have considerable power for estimating local LD patterns. The trios will provide useful information on the accuracy of the genotyping platforms being used for the project.
Choice of SNPs
A high density of SNPs is needed to describe adequately the genetic variation across the entire genome. When the project started, the average density of markers in the public database dbSNP (http:// www.ncbi.nlm.nih.gov/SNP/) 50 was approximately one every kilobase (2.8 million SNPs) but, given their variable distribution, many regions had a lower density of SNPs.
Further SNPs were obtained by random shotgun sequencing from whole-genome and whole-chromosome (flow-sorted) libraries 51 , using methods developed for the initial human SNP map 52 , and also by collaboration with Perlegen Sciences 36 and through the purchase of sequence traces from Applied Biosystems 53 for SNP detection (see Supplementary Information, part 2) . One useful result of this search for more SNPs is the confirmation of SNPs found previously. SNPs for which each allele has been seen independently in two or more samples ('double-hit' SNPs) have a higher average minor allele frequency than do 'single-hit' SNPs 28 . This leads to substantial savings in assay development. On 4 November 2003, the number of SNPs (with a unique genomic position) in dbSNP (build 118) was 5.7 million, and the number of double-hit SNPs was over 2 million. By February of 2004, 6.8 million SNPs (with a unique genomic position) are expected to be in dbSNP and available for the project, including 2.7 million double-hit SNPs.
As the extent of LD and haplotypes varies by 100-fold across the genome [30] [31] [32] 34, 35 , a hierarchical genotyping strategy has been adopted. In an initial round of genotyping, the project aims to genotype successfully 600,000 SNPs spaced at approximately 5-kilobase intervals and each with a minor allele frequency of at least 5%, in the 270 DNA samples. Priority is being given to previously validated SNPs, double-hit SNPs and SNPs causing amino-acid changes (as these may alter protein function). When these genotyping data are produced (by mid-2004; see below for details of data release), they will be analysed for associations between neighbouring SNPs. Additional SNPs will then be genotyped in the same DNA samples at a higher density only in regions where the associations are weak. Further rounds of analysis and genotyping will be carried out as required. It is expected that more than one million SNPs will be genotyped overall. This hierarchical strategy will permit regions of the genome with the least LD to be characterized at densities of up to one SNP per kilobase, maximizing the characterization of regions with associations only over short distances.
Genotyping
Each genotyping centre is responsible for genotyping all the samples for all the selected SNPs on the chromosome regions allocated (Table 1) . Among the centres, a total of five high-throughput genotyping technologies are being used, which will provide an opportunity to compare their accuracy, success rate, throughput and cost. Access to several platforms is an advantage for the project, as a SNP assay that fails on one platform may be developed successfully using another method in order to fill a gap in the HapMap. All platforms will be evaluated using a common set of performance criteria to ensure that the quality of data produced for the project meets a uniformly high standard.
Genotype quality is being assessed in three ways. First, at the beginning of the project, all centres were assigned the same randomly selected set of 1,500 SNPs for assay development and genotyping in the 90 CEPH DNA samples being used for the project. Genotyping centres produced data that were on average more than 99.2% complete and more than 99.5% accurate (as compared to the consensus of at least two other platforms). Second, every genotyping experiment includes samples for internal quality checks, with each 96-well plate containing duplicates of five different samples, and one blank. In addition, the data from trios provide a check for consistent mendelian inheritance of SNP alleles. For all the populations, the data from the unrelated samples provide a check that the SNPs are in Hardy-Weinberg equilibrium (a test of genetic mating
Box 1 Community engagement, public consultation and individual consent
As no personally identifiable information will be linked to the samples, the risk that an individual will be harmed by a breach of privacy, or by discrimination based on studies that use the HapMap, is minimal. However, because tag SNPs for future disease studies will be chosen on the basis of haplotype frequencies in the populations included in the HapMap, the data will be identified as coming from one of the four populations involved, and it will be possible to make comparisons between the populations. As a result, the use of population identifiers may create risks of discrimination or stigmatization, as might occur if a higher frequency of a disease-associated variant were to be found in a group and this information were then overgeneralized to all or most of its members 64 . It is possible that there are other culturally specific risks that may not be evident to outsiders 65 . To identify and address these group risks, a process of community engagement, or public consultation, was undertaken to confer with members of the populations being approached for sample donation about the implications of their participation in the project 66, 67 . The goal was to give people in the localities where donors were recruited the opportunity to have input into the informed consent and sample collection processes, and into such issues as how the populations from which the samples were collected would be named. Community engagement is not a perfect process, but it is an effort to involve potential donors in a more extended consideration of the implications of a research project before being asked to take part in it 68 . Community engagement and individual informed consent were conducted under the auspices of local governments and ethics committees, taking into account local ethical standards and international ethical guidelines. As in any cross-cultural endeavour, the form and outcome of the processes varied from one population to another. A Community Advisory Group is being set up for each community to serve as a continuing liaison with the sample repository, to ensure that future uses of the samples are consistent with the uses described in the informed consent documents. A more detailed article discussing ethical, social and cultural issues relevant to the project, and describing the processes used to engage donor populations in identifying and evaluating these issues, is in preparation.
patterns). Although a small proportion of SNPs may fail these checks for biological reasons, they more typically fail if a genotyping platform makes consistent errors, such as undercalling heterozygotes. Third, a sample of SNP genotypes deposited by each centre will be selected at random and re-genotyped by other centres. These stringent third-party evaluations of quality will ensure the completeness and reliability of the data produced by the project.
Data release
The project is committed to rapid and complete data release, and to ensuring that project data remain freely available in the public domain at no cost to users. The project follows the data-release principles of a 'community resource project' (http://www.wellcome. ac.uk/en/1/awtpubrepdat.html).
All data on new SNPs, assay conditions, and allele and genotype frequencies will be released rapidly into the public domain on the internet at the HapMap Data Coordination Center (DCC) (http:// www.hapmap.org/) and deposited in dbSNP. Individual genotype and haplotype data initially will be made available at the DCC under a short-term 'click-wrap' licence agreement. This strategy has been adopted to ensure that data from the project cannot be incorporated into any restrictive patents, and will thus remain freely available in the long term. The only condition for data access is that users must agree not to restrict use of the data by others and to share the data only with others who have agreed to the same condition. When haplotypes are defined in a region, then the individual genotypes, haplotypes and tag SNPs in that region will be publicly released to dbSNP, where there are no licensing conditions. Project participants have agreed that their own laboratories will access the data through the DCC and under the click-wrap licence, ensuring that all scientists have equal access to the data for research.
The consortium believes that SNP, genotype and haplotype data in the absence of specific utility do not constitute appropriately patentable inventions. Specific utility would involve, for example, finding an association of a SNP or haplotype with a medically important phenotype such as a disease risk or drug response. The project does not include any phenotype association studies. However, the data-release policy does not block users from filing for appropriate intellectual property on such associations, as long as any ensuing patent is not used to prevent others' access to the HapMap data.
Data analysis
The project will apply existing and new methods for analysis and display of the data. LD between pairs of markers will be calculated using standard measures such as D 0 (ref. 54), r 2 (refs 55, 56) and others. Various methods are being evaluated to define regions of high LD and haplotypes along chromosomes. Existing methods include 'sliding window' LD profiles 57, 58 , LD unit maps 59 , haplotype blocks 31, 35 and estimates of meiotic recombination rates along chromosomes 35, [60] [61] [62] . After analysis of the LD in the first phase of the project, regions in which there is little or no LD will be identified and ranked for further SNP selection and genotyping. Methods to select optimal collections of tag SNPs will be developed and evaluated (see above). The project will thus provide views of the data and tag SNPs that will be useful to the research community. As all data and analysis methods will be made available, other researchers will also be able to analyse the data and improve the analysis methods.
To assist optimization of SNP selection and analysis of LD and haplotypes, a pilot study is underway to produce a dense set of genotypes across large genomic regions. Ten 500-kilobase regions of the genome (see Supplementary Information, part 3 ) will be sequenced in 48 unrelated HapMap DNA samples (16 CEPH (currently being sequenced), 16 Yoruba, 8 Japanese and 8 Han Chinese). All SNPs identified, as well any additional SNPs in the public databases, will be genotyped in all of the 270 HapMap DNA samples, and the genotype data will be released following the guidelines described above. This study will provide dense genotype data for developing methods for SNP selection and for assessing the completeness of the information extracted, to guide the later stages of genotyping.
When the HapMap is used to examine large genomic regions, the problem of multiple comparisons will arise from testing tens to hundreds of thousands of SNPs and haplotypes for disease associations. This will lead to difficulty in separating true from false-positive results. Thus, new statistical methods, replication studies and functional analyses of variants will be important to confirm the findings and identify the functionally important SNPs.
Conclusion
The goal of the International HapMap Project is to develop a research tool that will help investigators across the globe to discover the genetic factors that contribute to susceptibility to disease, to protection against illness and to drug response. The HapMap will provide an important shortcut to carry out candidate-gene, linkagebased and genome-wide association studies, transforming an unfeasible strategy into a practical one. In its scope and potential consequences, the International HapMap Project has much in common with the Human Genome Project, which sequenced the human genome 63 . Both projects have been scientifically ambitious and technologically demanding, have involved intense international collaboration, have been dedicated to the rapid release of data into the public domain, and promise to have profound implications for our understanding of human biology and human health. Whereas the sequencing project covered the entire genome, including the 99.9% of the genome where we are all the same, the HapMap will characterize the common patterns within the 0.1% where we differ from each other.
For the full potential of the HapMap to be realized, several things must occur. The technology for genotyping must become more cost efficient, and the analysis methods must be improved. Pilot studies with other populations must be completed to confirm that the HapMap is generally applicable, with consideration given to expanding the HapMap if needed so that all major world populations can derive the greatest benefit. To use the tools created by the HapMap, later projects must establish carefully phenotyped sets of affected and unaffected individuals for many common diseases in a way that preserves confidentiality but retains detailed clinical and environmental exposure data. Longitudinal cohort studies of hundreds of thousands of individuals will also be invaluable for assessing the genetic and environmental contributions to disease.
Careful and sustained attention must also be paid to the ethical issues that will be raised by the HapMap and the studies that will use it. By consulting members of donor populations about the consent process and the implications of population-specific findings before sample collection, the project has helped to advance the ethical standard for international population genetics research. Future population genetics projects will continue to refine this approach. It will be an ongoing challenge to avoid misinterpretations or misuses of results from studies that use the HapMap. Researchers using the HapMap should present their findings in ways that avoid stigmatizing groups, conveying an impression of genetic determinism, or attaching incorrect levels of biological significance to largely social constructs such as race.
The HapMap holds much promise as a powerful new tool for discovery-to enhance our understanding of the hereditary factors involved in health and disease. Realizing its full benefits will involve the close partnership of basic science researchers, population geneticists, epidemiologists, clinicians, social scientists, ethicists and the public.
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